<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066504</url>
  </required_header>
  <id_info>
    <org_study_id>CLDE225A2404</org_study_id>
    <nct_id>NCT04066504</nct_id>
  </id_info>
  <brief_title>Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma</brief_title>
  <acronym>NISSO</acronym>
  <official_title>A Non-interventional, Multi-national, Multi-center Post-authorization Safety Study (PASS) to Assess the Long Term Safety and Tolerability of Odomzo (Sonidegib) Administered in Patients With Locally Advanced Cell Carcinoma (laBCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <brief_summary>
    <textblock>
      Collect real world safety data on the use of sonidegib in adult patients with laBCC. Document
      major safety parameters such as on treatment deaths, adverse events (AEs)/ serious adverse
      events (SAEs) and discontinuation secondary to AEs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, multinational, multi-center post-authorization safety study
      (PASS), to assess the safety of sonidegib administered in routine clinical practice in
      patients with laBCC who are not amendable to curative surgery or radiation therapy. This
      study is observational in nature and does not impose a therapy protocol,
      diagnostic/therapeutic interventions or a specific visit schedule. For this study, each
      enrolled patient will be followed up for 3 years after enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with AEs/SAEs</measure>
    <time_frame>3 years</time_frame>
    <description>including on-treatment deaths and discontinuation due to AEs/SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with AEs of special interest (AESI) or populations</measure>
    <time_frame>3 years</time_frame>
    <description>in patients with: relevant polymorphism, ≥65 yrs, hepatic or renal impairment, female patients with child bearing potential using anticonceptives, anemia (hemoglobin &lt;9 g/dL), recent myocardial ischemia or cardiac failure, concomitant medications with known risk of creatine kinase elevation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sonidegib</arm_group_label>
    <description>Patients with laBCC undergoing sonidegib treatment in routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sonidegib</intervention_name>
    <description>Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)</description>
    <arm_group_label>Sonidegib</arm_group_label>
    <other_name>LDE225</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with laBCC undergoing treatment with sonidegib.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent or equivalent document (e.g., written information) as per
             country regulation

          -  Patients aged 18 years or older with a diagnosis of laBCC who are not amenable to
             curative surgery or radiation therapy

          -  Patients must be treated with sonidegib 200 mg orally taken once daily (dose
             modifications according to the approved local country prescribing information are
             permitted)

          -  Sonidegib treatment must be started either at the first visit for this study or prior
             to study entry.

        Exclusion Criteria:

          -  Patients treated with any hedgehog pathway inhibitor besides sonidegib within 3 months
             prior to study entry

          -  Patients currently enrolled in an interventional clinical trial

          -  Hypersensitivity to the active substance or to any of the excipients listed in section
             6.1 of the Summary of Product Characteristics (SmPC)

          -  Pregnancy and breast-feeding

          -  Women of childbearing potential who do not comply with the Odomzo Pregnancy Prevention
             Programme (as defined in sections 4.4 and 4.6 of the approved SmPC).

          -  Male patients who are unable to follow or comply with the required contraception
             measures (as defined in sections 4.4 and 4.6 of the approved SmPC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Gutzmer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haut-Tumor-Zentrum Hannover</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf Gutzmer</last_name>
    <phone>4951153207672</phone>
    <email>Gutzmer.Ralf@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Katholisches Klinikum Bochum St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elbe Kliniken Stade - Buxtehude GmbH</name>
      <address>
        <city>Buxtehude</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DRK-Krankenhaus Chemnitz-Rabenstein</name>
      <address>
        <city>Chemnitz</city>
        <zip>'09117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>'30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaets-Hautklinik Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautklinik (Dermatology) Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fachklinik Muenster-Hornheide</name>
      <address>
        <city>Münster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios St. Elisabeth Klinik</name>
      <address>
        <city>Oberhausen</city>
        <zip>46045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harzklinikum Dorothea Christiane Erxleben GmbH</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced basal cell carcinoma</keyword>
  <keyword>laBCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

